Clean Power Hydrogen - Final Results
Clean Power Hydrogen plc
("CPH2" or the "Company")
Financial Results for the Financial Year ended
Clean Power Hydrogen plc (AIM: CPH2), the
Highlights - FY25
· First operation of scaled MFETM technology operating on a customer site, with the Company's demonstrator electrolyser (MFE110) successfully completing its Site Acceptance Test ("SAT") as validated by the customer. This confirmed CPH2's market disruptive MFE technology working at scale on a customer site for the first time.
· Successful prolonged production of high purity hydrogen in excess of 99.999vol% and 99.7wt% purity oxygen at the customer's site. Hydrogen generated with CPH2's technology exceeds fuel cell grade purity (ISO 14687). The oxygen generated exceeds medical grade purity. The high purity levels of hydrogen and oxygen allow for a wider range of potential industrial applications and enables customers to significantly improve project economics with two high value co-products.
· First time appointment of an internationally experienced Chief Commercial Officer,
· During 2025 the Company submitted first manufacturing and design documents ("licence package") to Hidrigin and Jones Engineering for review and study in advance of manufacturing preparations in
· MoU signed with Constant Energy for supply of an initial five 1MW MFE220 next generation units.
· During the year the Company announced the design for a 5MW unit had been initiated with an initial engineering assessment that the 5MW can achieve class-leading efficiency of 48kWh/kg.
Financial highlights - 2025
· Loss of
· Cash and cash equivalents of
· Successful fundraises completed receiving
·
Highlights - post-year end
· Siemens formal engagement commenced on
· A non-binding MoU announced with Koch Modular Process Systems LLC (subsidiary of Koch Industries) on
· On
· First 1MW Membrane-Free Electrolyser passed the Factory Acceptance Test ("FAT") levels 1 and 2 during H1 2026. As announced on
· On
· On
· On
· On
Commenting, Outgoing Chief Executive Officer of CPH2,
Annual Report
The Annual Report will be available on the Company's website today (https://www.cph2.com) and hard copies are expected to be posted to Shareholders on
Enquiries:
|
Clean Power Hydrogen plc |
+44 (0)130 232 8075 |
|
|
|
|
|
|
|
|
|
|
Cavendish Capital Markets Limited - NOMAD & Joint Broker |
|
|
|
+44 (0)131 220 9771 |
|
|
+44 (0)131 220 9772 |
|
Hanna Leijonmarck |
+44 (0)20 3772 6029 |
|
|
|
|
Turner Pope Investments (TPI) Limited - Joint Broker |
|
|
|
+44 (0)20 3657 0050 |
|
|
|
Background on CPH2
CPH2 is the holding company of Clean Power Hydrogen Group Limited which has a decade of dedicated research and product development experience that has delivered global patents in breakthrough hydrogen and oxygen production technology. The Group's strategic objective is to deliver the lowest lifetime LCOH in the market in relation to the production of hydrogen for the growing electrolysis or decentralised markets and alternative energy markets. CPH2 is listed on the AIM market and trades under the ticker AIM:CPH2.
For more information: https://www.cph2.com
CHAIRMAN'S STATEMENT
I am pleased to present the Annual Report of Clean Power Hydrogen plc ("CPH2") for the year ended
Much ill-informed debate remains around the production of hydrogen on a commercial basis. The reality is that the hydrogen market continues to grow globally, especially in regions outside of
At CPH2 we have developed patented technology for the production of high purity hydrogen and above medical-grade oxygen. Our Membrane-Free Electrolyser ("MFE™") solutions are market disruptive and leading edge. However, advanced innovation is no stranger to challenges and delay. During
Legacy electrolysis solutions can be inefficient and unreliable. This is why CPH2 has been pursuing breakthroughs to old thinking; that path is never straight forwards. We have secured proprietary technology designed to maintain efficiency across the variable power of wind and solar. By eliminating the fragile and expensive membrane at the heart of other electrolyser approaches we aim to lower capital costs and improve reliability. The combined effect is projected to deliver one of the lowest lifetime levelised costs of hydrogen produced. CPH2 will now be focused on developing these solutions and has made a strategic choice to pivot away from capital intensive electrolyser manufacturing and costly testing, towards exploiting its extensive IP, intangible assets and know-how, globally.
During the year CPH2 surpassed other milestones. We commenced the Front-End Engineering Design ("FEED") on a 5MW electrolyser arrangement using the same technology, with our ongoing Research & Development ("R&D") programme targeting world-leading efficiency.
To support continued progress during 2025 we successfully raised gross proceeds of approximately
Board and senior management
To lead our new strategy,
Richard has over 30 years' experience in the energy sector, spanning senior commercial management, business and market development roles in Europe, USA and the
On successful completion of the Fundraising, I will step down from the board and
Outlook
I cannot overstate the commitment that has been shown by our management team and staff to achieve the considerable scientific, testing, production and commercial progress, despite the setbacks that often accompany leading edge development. Their dedication is greatly appreciated by me as I leave the Company in good hands. It has been an honour and privilege to serve as Chairman of a great British innovator. I pass on the baton at the point we have identified a strong and credible commercial opportunity through our evolving strategy in the expanding hydrogen industry, which the Company can capture for the benefit of our shareholders.
Christopher Train
Chair
CHIEF EXECUTIVE'S REVIEW
The last year was characterised by strong progress and major milestones passed until we then suffered a major delay in our innovation programme which prompted an important change of strategy. Our market disrupting MFE220 electrolyser was at the very end of its final testing when a failure occurred. This is a reality of developing leading-edge technology. The most important fact is that no personnel were injured when containment was lost.
It is greatly encouraging that the Group's proprietary membrane-free stack and associated separators were not the cause of the incident. We're already working hard to define the root cause and make the changes required. However, as a result, the company is changing strategy to focus on technology development and global licensing. We are now able to target a much broader customer base and leverage existing commercial relationships, even previous competitors, globally.
As announced, we have signed Heads of Terms for an exclusivity period to complete a Strategic Partnership and Manufacturing and Technology Development Agreement with Hidrigin. If completed they would serve as our exclusive manufacturing partner in the
The Company's membrane-free technology has been described by customers as the 'standout solution', and our existing intellectual property commands substantial commercial value. Therefore, we have begun executing a capital-light business model, as exemplified by the arrangement with Hidrigin. It will focus on our proven capabilities in research and development, electrolyser stack manufacture, and the ability to successfully licence fully secured intellectual property.
To date we have been granted 16 patents across 12 jurisdictions, including
Commercial Progress
The Company's R&D and Engineering teams commenced the ("FEED") process on a 5MW unit during the year. The initial engineering assessment is that the 5MW and later generation 1MW unit designs can achieve world class leading efficiency of 48kWh/kg, with the opportunity to incorporate learning for the testing incident, as the final report becomes available. Efficiency could be further bolstered by leading stack reliability and the absence of membrane efficiency degradation seen in other categories.
The successful completion of the Site Acceptance Test ("SAT") in
Licensees
We have intensified our focus on activating licensee partnerships around the world. During the period, CPH2 submitted manufacturing and design licence documentation to both Hidrigin in
These submissions mark an important step in advancing CPH2's capital-light licensing model, with Hidrigin progressing plans to deploy CPH2 licensed electrolysers across Irish solar and wind projects under its 20-year 2GW licence, and Bentec moving towards production under its 2GW licence across parts of
Building Partnerships
The Company announced engagement with Siemens, as part of a non-binding MoU to support technology development. In addition, we signed a similar arrangement with Koch Modular Process Systems LLC to explore manufacturing or licensing in USA,
People
I will be stepping down from the role of Chief Executive Officer during
Richard has over 30 years' experience in the energy sector, 8 of which were specifically in Hydrogen developing plants in the
A new leadership team is already driving day to day progress and a brief transition to our revised strategy. Our dedicated professionals are the bedrock of our achievements and future success. I remain proud of the whole team we have built at CPH2, their major successes in the first half of the period and ability manage innovation challenges in the latter half.
Our primary focus over the coming year will be activating our existing licensees and securing new partners as we pivot to a technology development and licensing business.
As I depart, I would like to extend my gratitude to our employees, shareholders and partners for their enduring support. We believe we have significant commercial opportunities to pursue with our unique technology. On your behalf the new team is to offer safe, lower cost and more reliable hydrogen and oxygen solutions to the growing hydrogen industry. The Company has the people, knowledge and partners, combined with an unwavering drive to meet our business goals.
Chief Executive Officer
FINANCIAL REVIEW
Introduction
The 2025 year demonstrated a continued laser focus on correct capital allocation to facilitate the Company's success in achieving its key milestones, while keeping tight control of expenditure over other activities. Following the incident on
The first tranche of a fundraise on
Review of financial statements
The Company incurred a loss of
Administrative expenses
Administrative expenses were
Impairment losses
Total impairment-related charges in 2025 were
Onerous contract losses
Following a review of the Group's electrolyser sales contracts, one contract continued to meet the criteria of an onerous contract in 2025. A
Taxation
The taxation credit for 2025 was
Capitalised development costs
Capitalised development costs incurred during 2025 were
Cash
Cash and cash equivalents at
Accounting treatment of the incident
The incident that occurred on
Going concern
On the
The Directors consider that there is a reasonable basis to expect the proposed fundraising to complete and, on that basis, that the Company and the Group will have adequate resources to continue in operational existence for at least twelve months from the date of approval of the financial statements. Accordingly, the Directors consider it appropriate to prepare the financial statements on a going concern basis. However, as completion of the second tranche is not wholly within the Group's control at the date of approval of the financial statements, this condition indicates the existence of a material uncertainty which may cast doubt on the Company's and the Group's ability to continue as a going concern.
Upon reviewing the financial forecasts and carefully considering a number of scenarios, these show that the Company and the Group will be able to operate within the level of cash reserves and that Directors have a reasonable expectation that CPH2 have adequate resources to continue in operational existence for a period of 12 months from the date of approval of these financial statements and consider the going concern basis to be appropriate.
Outlook
Whilst the incident has been very disappointing, I am pleased to say that following an accelerated restructuring and repositioning program, combined with the fundraise, CPH2 is well-positioned to capitalise on its valuable intellectual property portfolio in a more sustainable, lower cost manner.
Chief Financial Officer
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the year ended
|
|
|
2025 |
2024 |
|
|
|
£'000 |
£'000 |
|
Other operating income |
|
- |
334 |
|
Administrative expenses |
|
(6,484) |
(5,704) |
|
Impairment losses |
|
(77) |
(9,124) |
|
Onerous contract losses |
|
(1,029) |
(538) |
|
Operating loss |
|
(7,590) |
(15,032) |
|
Finance income |
|
69 |
134 |
|
Finance expense |
|
(41) |
(47) |
|
Loss before taxation |
|
(7,562) |
(14,945) |
|
Taxation |
|
486 |
508 |
|
Loss for the financial year |
|
(7,076) |
(14,437) |
|
Other comprehensive expense |
|
|
|
|
Items that may be reclassified subsequently to profit or loss: |
|
|
|
|
Foreign currency translation differences |
|
(24) |
19 |
|
Fair value decrease in respect of investments |
|
- |
(355) |
|
Total comprehensive expense for the year |
|
(7,100) |
(14,773) |
|
Basic and diluted earnings per share (pence) |
|
(1.80) |
(5.37) |
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at
|
|
|
|
|
31 December 2024
|
|
|
|
|
£'000 |
£'000 |
|
Assets |
|
|
|
|
|
Non-current assets |
|
|
|
|
|
Intangible assets |
|
|
5,568 |
4,608 |
|
Property, plant and equipment |
|
|
1,185 |
1,535 |
|
Other receivables |
|
|
120 |
120 |
|
|
|
|
6,873 |
6,263 |
|
Current assets |
|
|
|
|
|
Inventories |
|
|
2,398 |
1,614 |
|
Trade and other receivables |
|
|
1,577 |
1,476 |
|
Cash and cash equivalents |
|
|
3,953 |
327 |
|
|
|
|
7,928 |
3,417 |
|
Total assets |
|
|
14,801 |
9,680 |
|
Liabilities |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
|
(1,677) |
(1,275) |
|
Lease liabilities |
|
|
(175) |
(198) |
|
|
|
|
(1,852) |
(1,473) |
|
Non-current liabilities |
|
|
|
|
|
Deferred income |
|
|
(751) |
(1,166) |
|
Lease liabilities |
|
|
(450) |
(626) |
|
|
|
|
(1,201) |
(1,792) |
|
Total liabilities |
|
|
(3,053) |
(3,265) |
|
Net assets |
|
|
11,748 |
6,415 |
|
Equity |
|
|
|
|
|
Called up share capital |
|
|
5,020 |
2,697 |
|
Share premium account |
|
|
37,725 |
27,745 |
|
Merger reserve |
|
|
3,702 |
3,702 |
|
Currency translation reserve |
|
|
(11) |
13 |
|
Accumulated loss |
|
|
(34,688) |
(27,742) |
|
Total equity |
|
|
11,748 |
6,415 |
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended
|
|
Called up share capital |
Share premium account |
Merger reserve |
Foreign currency reserve |
Accumulated loss |
Total equity |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
Balance as at |
2,682 |
27,707 |
3,702 |
(6) |
(13,132) |
20,953 |
|
Loss for the financial year |
- |
- |
- |
- |
(14,437) |
(14,437) |
|
Other comprehensive expense |
- |
- |
- |
19 |
(355) |
(336) |
|
Total comprehensive expense for the year |
- |
- |
- |
19 |
(14,792) |
(14,773) |
|
Share based payments |
- |
- |
- |
- |
182 |
182 |
|
Issue of share capital |
15 |
38 |
- |
- |
- |
53 |
|
Balance as at |
2,697 |
27,745 |
3,702 |
13 |
(27,742) |
6,415 |
|
Loss for the financial year |
- |
- |
- |
- |
(7,076) |
(7,076) |
|
Other comprehensive expense |
- |
- |
- |
(24) |
- |
(24) |
|
Total comprehensive expense for the year |
- |
- |
- |
(24) |
(7,076) |
(7,100) |
|
Share based payments |
- |
- |
- |
- |
130 |
130 |
|
Issue of share capital |
2,323 |
9,980 |
- |
- |
- |
12,303 |
|
Balance as at |
5,020 |
37,725 |
3,702 |
(11) |
(34,688) |
11,748 |
CONSOLIDATED CASH FLOW STATEMENT
For the year ended
|
|
|
2025 |
2024 |
|
|
|
£'000 |
£'000 |
|
Cash flow from operating activities |
|
|
|
|
Loss for the financial year |
|
(7,076) |
(14,437) |
|
Adjustment for: |
|
|
|
|
Depreciation and amortisation |
|
519 |
532 |
|
Impairment losses |
|
77 |
9,124 |
|
Onerous contract losses |
|
167 |
538 |
|
Disposal |
|
(112) |
(8) |
|
Share based payments |
|
130 |
182 |
|
Foreign exchange |
|
(34) |
29 |
|
Net finance income |
|
(28) |
(87) |
|
Taxation credit |
|
(486) |
(508) |
|
Changes in working capital: |
|
|
|
|
Increase in inventories |
|
(784) |
(824) |
|
Increase in trade and other receivables |
|
(151) |
(127) |
|
Decrease in trade and other payables |
|
(181) |
(914) |
|
Cash used in operations |
|
(7,959) |
(6,500) |
|
Income tax received |
|
536 |
608 |
|
Net cash used in operating activities |
|
(7,423) |
(5,892) |
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Current asset investments withdrawn |
|
- |
6,000 |
|
Purchase of property, plant and equipment |
|
(37) |
(241) |
|
Proceeds from sale of plant and equipment |
|
- |
22 |
|
Purchase of intangible assets |
|
(1,046) |
(2,752) |
|
Proceeds from sale of investments |
|
- |
704 |
|
Net cash generated from investing activities |
|
(1,083) |
3,733 |
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Issue of share capital (net of costs) |
|
12,303 |
53 |
|
Interest received |
|
69 |
134 |
|
Interest paid |
|
(41) |
(47) |
|
Payment of lease liabilities |
|
(199) |
(122) |
|
Net cash generated from financing activities |
|
12,132 |
18 |
|
|
|
|
|
|
Net increase/(decrease) in cash and cash equivalents |
|
3,626 |
(2,141) |
|
Cash and cash equivalents at the beginning of the year |
|
327 |
2,468 |
|
Cash and cash equivalents at the end of the year |
|
3,953 |
327 |
CONSOLIDATED CASH FLOW STATEMENT
For the year ended
1 Summary of significant accounting policies and general information
Clean Power Hydrogen plc is a public company incorporated in the
The Group financial statements have been prepared in accordance with
The Parent Company financial statements have been prepared under applicable United Kingdom Accounting Standards (FRS101 'Reduced Disclosure Framework'). The principal accounting policies applied in the preparation of these consolidated and separate financial statements are set out below.
These policies have been consistently applied to all the years presented, unless otherwise stated.
The financial statements are drawn up in Sterling, the functional currency of the company and the Group. The level of rounding for the financial statements is the nearest thousand pounds.
The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2 of the Annual Report.
Exemptions
FRS 101 allows a qualifying entity certain disclosure exemptions, subject to certain conditions, which have been complied with, and the Company has taken advantage of the following exemptions:
· IAS 7 Statement of cash flows;
· IFRS 7 Financial instruments disclosures;
· IAS 24 Key management remuneration.
Basis of consolidation and merger accounting
The Company was incorporated on
The consolidated financial statements present the results of the Company and its subsidiaries ("the Group") as if they have always formed a single group. Intercompany transactions and balances between Group companies are therefore eliminated in full. The share capital presented is that of Clean Power Hydrogen plc with the difference on elimination of CPHGL's capital being shown as a merger reserve.
Subsidiaries are all entities over which the Group has control. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group and cease to be consolidated from the date on which control is transferred out of the Group.
Going concern
The Board has assessed going concern for the period to
In assessing the Group's and Company's ability to continue as a going concern, the Board has prepared cash flow forecasts for the period to
Provided both tranches of the fundraising complete as planned, the forecasts indicate that the Company and the Group will have sufficient cash resources to meet their liabilities as they fall due throughout the going concern assessment period. The Directors therefore consider that there is a reasonable basis to expect the proposed fundraising to complete and, on that basis, that the Company and the Group will have adequate resources to continue in operational existence for at least twelve months from the date of approval of these financial statements. Accordingly, the Directors consider it appropriate to prepare the financial statements on a going concern basis. However, completion of the second tranche, which is subject to approval of the necessary share issuance authorities at a general meeting, is required to provide sufficient funding for the full going concern assessment period and is not wholly within the Group's control at the date of approval of these financial statements. This condition indicates the existence of a material uncertainty which may cast doubt on the Company's and the Group's ability to continue as a going concern. These financial statements do not include the adjustments that would result if the Company or the Group were unable to continue as a going concern.
ENDS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE